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The aim of this study was to evaluate the usefulness of
maternal serum markers in the early prenatal diagnosis of
molar pregnancies. The ultrasound features, cytogenetic
and histopathological findings of 10 cases of molar
pregnancy diagnosed at 11–13 weeks of gestation were
compared retrospectively with the maternal serum con-
centrations of human chorionic gonadotrophin (HCG),
alpha fetoprotein (AFP), pregnancy-associated plasma
protein A (PAPP-A) and pregnancy-specific b1-glycoprotein
(SP1). Free b-HCG and intact HCG concentrations were
very high [ù2.5 multiples of the median (MoM)] in all
cases. AFP concentrations were extremely low in all cases
of singleton complete moles (ø0.5 MoM) and were high in
one case of twin complete mole, in one case of triploid
partial mole and two cases of euploid partial mole
(ù2.5 MoM). Serum PAPP-A and SP1 were high in com-
plete moles. The combined use of ultrasound features,
maternal serum proteins and fetal cytogenetic findings
should enable the early differential diagnosis in utero
and perinatal management of those molar pregnancies
presenting with an anatomically normal fetus.
Key words: complete mole/partial mole/placenta/pregnancy/
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Introduction
Classical hydatidiform moles were distinguished from partial
mole from the late 1970s on the basis of gross morphological,
histological and cytogenetic criteria (Szulman and Surti, 1978a,
b). Postnatally, classical or complete hydatidiform moles are
characterized by generalized swelling of the villous tissue,
diffuse trophoblastic hyperplasia and the absence of embryonic
or fetal tissue. Following uterine evacuation, 18–29% of
patients with a classical mole will develop a persistent tropho-
blastic tumour (Berkowitz and Goldstein, 1996). Classical
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moles have a diploid chromosomal constitution totally derived
from the paternal genome (Kajii and Ohama, 1977).
Morphologically, partial hydatidiform moles are charac-
terized by focal swelling of the villous tissue, focal tropho-
blastic hyperplasia and embryonic or fetal tissue (Szulman and
Surti 1978a, b). Partial moles are mainly triploid, having
inherited one maternal and two paternal sets of chromosomes
(Jacobs et al., 1982). Patients with a partial mole are also at
risk (1–10%) of developing both the non-metastatic and
metastatic forms of gestational trophoblastic disease (Bagshawe
et al., 1990).
Ultrasonography has replaced all other means of establishing
the screening of molar pregnancies in utero (Jauniaux, 1998).
However, if ultrasound can detect villous hydatidiform trans-
formation it provides no information on the trophoblast activity.
An increasing number of conditions presenting with ultrasound
features suggesting a molar pregnancy have been reported,
making prenatal differential diagnosis difficult (Steller et al.,
1994a; Nwosu et al., 1995; Chen 1997; Chen et al., 1997;
Jauniaux and Nicolaides, 1997). Because they have a different
outcome, partial moles must be distinguished from classical
moles with a co-existing fetus and from benign hydropic
degeneration of the placenta. To this purpose we have examined
the usefulness of maternal serum protein markers in the
prenatal diagnosis and perinatal management of molar
pregnancies detected in early pregnancy by ultrasound.
Materials and methods
Patients
A retrospective investigation was conducted on all cases of complete
and partial hydatidiform mole diagnosed prenatally at 11–13 weeks
of gestation and for which maternal serum had been stored and a
detailed histopathological examination had been performed. The
maternal and fetal charts were reviewed for the following charac-
teristics: maternal age, gravidity, medical and pregnancy history,
reasons for referral for ultrasound examination, ultrasound findings,
prenatal diagnostic procedures and pregnancy complications. Gesta-
tional age was calculated from the menstrual history and confirmed
by ultrasound measurements of the fetus in cases of partial mole.
Follow-up data were available in all patients. In cases presenting
with placental molar changes, a detailed histopathological examination
was performed and if a trophoblastic abnormality was confirmed, the
mother was entered in the registry for molar pregnancies at Charing
Cross Hospital, London.
Protein assays
Maternal blood was collected from an antecubital vein at the time of
the first ultrasound examination. In pregnancies that continued,
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Table I. Clinical features in 10 pregnancies presenting with molar changes antenatally
Category Gestational Karyotype Maternal serum Maternal serum Outcome
age (weeks) HCG (MoM) AFP (MoM) (weeks)
Complete mole
1 Single A 11.6 46,XX 10.5 0.1 TOP (12)
Single B 12.0 46,XX 5.8 0.05 TOP (12)
Single C 12.3 46,XX 4.4 0.03 TOP (12)
2 Twin A 11.5 46,XX 12.9 2.5 TOP (14)
Twin B1 11.6 46,XX 17.2 2.3
Twin 2 20.4 10.2 0.9
Twin 3 24.3 10.3 N/A SVD (37)
3 Triplet 1 12.2 2X 46,XY 9.4 1.9
Triplet 2 14.2 16.2 1.2
Triplet 3 16.6 53.8 1.3 PIH (17)
Partial mole
4 Triploidy A 12.1 69,XXX 10.6 1.1 TOP (14)
Triploidy B 14.4 69,XXY 3.1 3.5 TOP (15)
5 Mes dyspl A1 12.2 46,XX 5.7 2.6
Mes dyspl 2 14.1 7.9 8.7
Mes dyspl 3 20.0 9.2 9.3
Mes dyspl 4 36.5 0.4 N/A EmCS (30)
Mes dyspl B1 13.4 46,XX 6.1 3.1
Mes dyspl 2 16.4 3.9 3.4
Mes dyspl 3 22.3 3.4 3.9
Mes dyspl 3 25.3 0.5 4.0 SVD (40)
HCG 5 human chorionic gonadotrophin; AFP 5 alpha fetoprotein; Mes dyspl 5 mesenchymal dysplasia;
MoM 5 multiples of the median; TOP 5 termination of pregnancy; SVD 5 spontaneous vaginal delivery;
PIH 5 pregnancy-induced hypertension; EmCS 5 emergency caesarian section
maternal serum continued to be collected as part of our clinical
protocol for the antenatal management of molar pregnancies includ-
ing measurement of β human chorionic gonadotrophin (β-HCG)
concentration and maternal thyroid function tests. Unused serum
samples were kept frozen at –40°C until assayed.
The concentrations of intact HCG, free α-HCG and free β-HCG
subunits were measured using solid-phase two-site immunoradio-
metric assay (IRMA) kits from BioMerieux (Marcy-l’Etoile, France).
These assays, using monoclonal antibodies, were calibrated against
the First International Reference Preparations 75/537 for HCG dimer,
75/569 for free α-HCG subunits and 75/551 for free β-HCG subunits.
Sensitivities were 1 mIU/ml for HCG and 0.03 mIU/ml for both
free subunits. Intra- and interassay coefficient of variation were,
respectively, ,7% and ,10% for each assay. The alpha-fetoprotein
(AFP) concentration was determined by an enzyme immunoassay
with a fluorometric end-point (Hybritech Inc., San Diego, CA, USA)
using the Stratus apparatus from Baxter (Dade Division, Miami, FL,
USA). The intra-assay coefficient of variation was 5%.
Pregnancy-associated plasma protein A (PAPP-A) was measured
in a double antibody sandwich enzyme immunoassay (ELISA)
developed in our laboratory (Bersinger et al., 1995). Briefly, the
polyclonal anti-PAPP-A antibody was purified in a negative affinity
step using the ,300 000 Da fraction of pooled pregnancy serum as
a solid phase in order to remove contaminating antibodies. The
purified immunoglobulin G was used as a coating antibody in the
assay. Sera were diluted 1:100 to 1:1000 prior to assay. The intra-
and inter-assay coefficients of variance were 4.3 and 10.2%,
respectively, for a PAPP-A concentration of 1.0 WHO mIU/ml.
Pregnancy-specific β1-glycoprotein (SP1) was determined by
microplate ELISA as previously described (Bersinger et al., 1994).
Serum dilutions were 1:2600 to 1:10 000 in PBS buffer containing
bovine serum albumin (BSA, 2% w/v) and Emulsit (0.05% v/v).
Intra- and inter-assay coefficients of variance were 4.1 and 8.7%,
respectively.
All serum marker concentrations were compared to the available
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normal ranges for unaffected pregnancies (Bersinger et al., 1994;
Nagy et al., 1994) and the results expressed as multiples of the
median (MoM) and when appropriate, corrected for multiple pregnan-
cies. Values .2.5 MoM were classified as high (Hsu et al., 1994;
Benn et al., 1996).
Results
Six pregnancies were attributed to the classical (complete)
mole group, including three singleton euploid complete moles
and three cases of multiple pregnancy combining a complete
mole and a normal gestational sac (Table I). The partial mole
group consisted of four pregnancies including two cases of
triploidy and two cases of euploid mesenchymal dysplasia. All
pregnancies followed a spontaneous conception.
Singleton complete moles were evacuated surgically
within 2 days of the ultrasound diagnosis. In cases where the
molar sonographic changes were associated with a fetus, the
parents were offered an invasive procedure to determine the
fetal karyotype. The type of procedure, i.e. chorionic villous
sampling (CVS), fetal blood sampling (FBS) or amniotic fluid
sampling (AFS), was carried out according to the presence of
co-existing fetal abnormalities, the gestational age at which
the parents reached their decision and the location of placenta
and molar mass inside the uterine cavity. Two fetuses of the
partial mole group presented with abnormalities on ultrasound
including increased nuchal thickness and holoprosencephaly.
In both cases, karyotyping revealed a triploidy and the parents
opted for a pregnancy termination. In one of the cases of twin
molar pregnancy, the parents also opted for a pregnancy
termination at 14 weeks because of the possible associated
perinatal risks. Multicystic ovaries were observed in all cases
of complete mole and in one case of partial triploid mole.
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Figure 1. Maternal serum concentration of β human chorionic gonadotrophin (HCG), HCG, α-HCG and alpha fetoprotein (AFP) in
multiples of the median (MoM) at the time of the first ultrasound examination (11–13 weeks) in three cases of singleton complete mole
(SCM), two cases of twin complete mole (TCM), one case of triplet complete mole (TrCM), two cases of triploidy (Trip) and two cases
of mesenchymal dysplasia (MD).
One case of twin complete mole, the case of triplet complete
mole and two cases of euploid partial mole were followed up.
The twin pregnancy combining a complete mole resulted in a
normal fetus at 37 weeks gestation. Chronic vaginal bleeding
was observed from 13 weeks but the mother never presented
with clinical or biological evidence of pregnancy-induced
hypertension and her chest X rays were normal before delivery.
The triplet pregnancy was complicated by severe pregnancy-
induced hypertension at 17 weeks requiring pregnancy termina-
tion. In both cases, the fetuses were anatomically normal at
delivery and pathological examination of the placenta con-
firmed the ultrasound diagnosis. In all cases of classical
mole and partial triploid mole, the villi showed respectively
generalized and focal hydropic changes and trophoblastic
hyperplasia. The two pregnancies presenting with euploid
partial moles had uncomplicated second trimesters. One case,
presenting with polyhydramnios and premature labour at 30
weeks gestation and the fetus in breech position, was delivered
by Caesarean section. The neonate was macrosomic (2.4 kg)
with macroglossa and ear lobe creases and was diagnosed to
be affected by Beckwith–Wiedemann syndrome. In these two
cases, the placenta was large, weighing respectively 1535 g
and 1430 g, and had a karyotype identical to that of the
corresponding fetus. Histopathological examination showed
aneurysmal dilatation of the chorionic vasculature and focal
villous hydrops with no abnormal trophoblastic proliferation.
Maternal serum hormonal analysis indicated that free β-
HCG and intact HCG concentrations were very high in all
cases. Free α-HCG concentration was only increased (.2.5
MoM) in the case of the triplet complete mole and was low
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in one of the two cases of triploid partial mole (Figure 1).
Maternal serum AFP concentration was extremely low
(,0.5 MoM) in all cases of singleton complete moles and
was high in one case of twin complete mole, in one case of
triploid partial mole and the two cases of mesenchymal
dysplasia. SP1 concentration was elevated in complete moles
whereas PAPP-A concentration was elevated in all cases except
in one case of partial triploid mole (Figure 2). At 17–20 weeks,
in the euploid partial moles, maternal serum HCG and maternal
serum β-HCG concentrations were within normal ranges and
the AFP was more than 3.5 MoM whereas in the twin and
triplet complete moles the maternal serum HCG and maternal
serum β-HCG were over 9 MoM and the AFP was within the
normal range (Table I).
Discussion
Detailed ultrasound examination can identify placental molar
transformation from the end of the first trimester (Jauniaux,
1998). The vast majority of classical and partial triploid moles
miscarry before 10–12 weeks of gestation (Jeffers et al., 1993).
In early pregnancy failure, the embryo often dies before the
first ultrasound examination. Thus the differential diagnosis of
molar changes in early pregnancy is essentially either classical
mole, triploid partial mole or benign hydropic placental reten-
tion. Although triploidy is less often associated with molar
changes in the first trimester of pregnancy than in the second
or third trimester, the use of standardized histological and/or
cytogenetic criteria is both accurate and reproducible in the
detection of complete and partial triploid mole (Jauniaux
et al., 1996a).
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Figure 2. Maternal serum concentration of pregnancy-specific β1-glycoprotein (SP1) and pregnancy-associated plasma protein A (PAPP-A)
in multiples of the median (MoM) at the time of the first ultrasound examination (11–13 weeks) in one case of singleton complete mole
(SCM), two cases of twin complete mole (TCM), one case of triplet complete mole (TrCM), one case of triploidy (Trip) and two cases of
mesenchymal dysplasia (MD).
The discovery, during the second trimester, of a pregnancy
with ultrasound features suggesting placental molar trans-
formation causes several diagnostic and management difficul-
ties. Within this context, there are four main categories of
pregnancy: classical hydatidiform mole; complete mole in a
multiple pregnancy; partial triploid mole; and focal benign
villous hydatidiform (pseudomolar) transformation (Jauniaux
and Nicolaides, 1997). The first three can be complicated by
persistent trophoblastic disease whereas the latter can be
associated with Beckwith–Wiedemann syndrome as in one
case in this series. An aberration in normal maternal suppression
of the IGF-2 gene could account for the Beckwith–Wiedemann
syndrome phenotype including the features of overgrowth
(Morison and Reeve, 1998), which can be associated with
congenital anomalies such as omphalocoele, mild microcephaly
and ear lobe creases. In these cases, the placental anomaly
appears to be a limited malformation of the extra-embryonic
mesoderm involving the mesenchyme and the vessels of the
stem villi of several cotyledons. It has been referred to as
mesenchymal dysplasia and it can be found with a pheno-
typically normal fetus (Jauniaux et al., 1997a) suggesting that
in some cases the overgrowth is limited to the placental
tissue. Confined placental diploidy or triploid mosaicism and
tetraploidy may also appear as a partial mole and can theoretic-
ally be complicated by persistent trophoblastic disease but
these cases are exceptional (Jauniaux, 1998).
The ultrasound demonstration of classical hydatidiform
mole is easy and accurate from 10 weeks of gestation. The
presence of any form of placental molar change and a coexistent
fetus continues to be referred to as partial mole (Nwosu et al.,
1995). However, theoretically, the histopathological definition
should only be applied when villous hydatidiform changes are
associated with trophoblastic hyperplasia, which cannot be
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demonstrated by ultrasound. If the placenta is partially molar
and the fetus is growth retarded with structural anomalies,
fetal karyotyping will usually demonstrate a triploidy (Jauniaux
et al., 1996b, 1997b). Thus the main difficulty will be the
differentiation between a complete mole coexisting with a
normal pregnancy and non-triploid (euploid) partial moles. A
classical mole may coexist with a normal fetus and placenta
in cases of molar transformation of one ovum in a dizygotic
twin or triplet pregnancy (Steller et al., 1994a). Because of
a high maternal complication rate, including pre-eclampsia,
hyperthyroidism, respiratory insufficiency and ovarian hyper-
stimulation (bilateral multicystic ovaries), this condition must
be distinguished from a true partial mole, as early in pregnancy
as possible. At the beginning of the second trimester, the
complete mole may be clearly separated from the normal
placenta (Jauniaux and Nicolaides, 1997). However, the mole
does not grow proportionally with the normal placenta and at
17–20 weeks it may partially cover the normal placenta,
making it difficult to distinguish on ultrasound from a true
partial mole.
The rate of differentiation of cytotrophoblast into syncytio-
trophoblast appears to be the main factor that leads to the
synthesis of HCG (Hay, 1988). HCG regulates the differenti-
ation of cytotrophoblast via its receptors and thus its own
synthesis (Rodway and Rao, 1995). Higher concentrations of
HCG-receptor mRNA and protein are found in hyperplastic
trophoblasts and HCG cannot self-regulate its synthesis under
this condition (Rodway and Rao, 1995). We found that the
concentration of intact HCG and free β-HCG was high
(.2.5 MoM) in all categories of complete and partial moles.
Although trophoblastic differentiation appears normal in
mesenchymal dysplasia, the important placental overgrowth
could explain the increased maternal serum HCG concentration
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found in the two cases in this study. In complete moles, intact
HCG and free β-HCG concentrations were higher than in
partial moles and continued to increase as pregnancy advanced
whereas free α-HCG concentration was only increased in the
case of triplet pregnancy combining a complete mole with a
normal twin pregnancy. By contrast, the AFP concentrations
were higher in most cases of partial mole. Fetal abnormalities
in partial triploid moles and abnormal vascular permeability
in mesenchymal dysplasia may explain the transfer of larger
quantities of this protein from fetal into maternal circulation.
Serum SP1 was high in complete moles whereas PAPP-A
concentrations were increased in complete moles and in one
case of mesenchymal dysplasia. Since the concentrations of
these two proteins vary strongly throughout gestation, the
measurement of these proteins is of limited value in the
management of molar pregnancies. Other biological markers
of trophoblastic cellular activity such as epidermal growth
factor, progesterone or interleukines have been investigated
in vitro or in the post-molar surveillance (Steller et al., 1994a,
b; Vasilev et al., 1994) but PAPP-A or SP1 are likely to be of
limited value during pregnancy. Investigation of the molecular
heterogeneity of urinary or serum HCG (Hoermann et al.,
1993) may help to further differentiate as well as follow up
women presenting with molar pregnancies and a normal fetus.
In cases of complete mole coexisting with a normal fetus
and placenta, the mother must be counselled about possible
perinatal complications and a therapeutic termination should
be considered at all stages in cases of severe maternal com-
plications. In ongoing pregnancies, an invasive procedure to
establish the fetal karyotype should be performed. Placental
biopsy may be technically difficult and misleading because
of confined mosaicism while needle aspiration could be
technically complicated by the presence of molar villi. Amnio-
centesis can be proposed for partial moles but may be difficult
in complete moles with a coexisting fetus due to the presence
of intrauterine bleeding and the anterior location of a large
molar mass. When the fetus is sonographically normal, fetal
blood sampling is a possible alternative at 18–20 weeks
of gestation. If the fetal karyotype was euploid, the fetus
apparently anatomically normal and the mother’s clinical
course stable, she should be offered bi-monthly follow-up
visits. These visits must include sonographic evaluation of
fetal anatomy and growth, blood pressure measurements, serum
HCG concentration and urine analysis. If the maternal serum
HCG concentration increases and the maternal serum AFP
decreases, thus confirming a multiple pregnancy combining a
classical mole and a normal conceptus, a monthly full blood
count and thyroid functional tests should be obtained and a
chest X ray should be performed every 3 months.
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